CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Class III antiarrhythmic
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises dronedarone, so inhibitors of this enzyme raise its levels. The strong inhibitor ketoconazole increased dronedarone levels 17-fold (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Cobicistat is a strong CYP3A inhibitor used to boost atazanavir or darunavir, and it raises the levels of drugs metabolised by CYP3A (cobicistat SmPC, EMA). The interaction table of the US cobicistat label shows increased dronedarone levels (cobicistat label, US Food and Drug Administration, FDA). Dronedarone prolongs the QT interval on the electrocardiogram, and the higher its concentration, the longer the QT (dronedarone FDA label). The reverse effect is also possible: dronedarone moderately inhibits CYP3A4, and CYP3A inhibitors slow the clearance of cobicistat and raise its levels (dronedarone and cobicistat SmPCs, EMA).
Symptoms
Higher dronedarone levels carry a risk of serious, including life-threatening, reactions such as cardiac arrhythmias (cobicistat label, US Food and Drug Administration, FDA). Dronedarone prolongs the QT interval on the electrocardiogram (ECG), and it is stopped if the Bazett-corrected QTc reaches 500 milliseconds or more (dronedarone summary of product characteristics, European Medicines Agency, EMA). QT prolongation itself causes no symptoms and shows only on the ECG.
Management
The combination is contraindicated. The US cobicistat label lists dronedarone among its contraindications without conditions because of the risk of serious and life-threatening reactions such as cardiac arrhythmias (cobicistat label, US Food and Drug Administration, FDA). In Europe, dronedarone is contraindicated by name with the tablets that combine cobicistat with darunavir or atazanavir (darunavir/cobicistat and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA). The EU SmPC of cobicistat itself does not name dronedarone. It contraindicates drugs that depend heavily on CYP3A for clearance and whose high levels are linked to serious or life-threatening reactions (cobicistat SmPC, EMA). The dronedarone SmPC and label contraindicate strong CYP3A4 inhibitors and name ritonavir, the other booster of the same drugs. Cobicistat is not on that list, although its own SmPC describes it as a strong CYP3A inhibitor (dronedarone SmPC, EMA, and FDA label; cobicistat SmPC, EMA). Before starting cobicistat and during treatment, consider possible interactions, review all concomitant medicines and monitor for their adverse effects (cobicistat FDA label). In dronedarone overdose, monitor heart rhythm and blood pressure and give supportive, symptom-based treatment. There is no specific antidote, and it is not known whether dialysis removes dronedarone (dronedarone SmPC, EMA). Correct low potassium or magnesium before starting dronedarone and during treatment. Stop dronedarone if the QTc interval on the electrocardiogram reaches 500 milliseconds or more (dronedarone SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- EMA: Ficha técnica: Cobicistat, Tybost (EU/1/13/872), sección 4.3 (2026)– EMA, Tybost 150 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5